247 related articles for article (PubMed ID: 36154176)
61. Effects of CFTR-modulator triple therapy on sinunasal symptoms in children and adults with cystic fibrosis.
Bode SFN; Rapp H; Lienert N; Appel H; Fabricius D
Eur Arch Otorhinolaryngol; 2023 Jul; 280(7):3271-3277. PubMed ID: 36738326
[TBL] [Abstract][Full Text] [Related]
62. Development of elexacaftor - tezacaftor - ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis.
Middleton PG; Taylor-Cousar JL
Expert Rev Respir Med; 2021 Jun; 15(6):723-735. PubMed ID: 33249928
[No Abstract] [Full Text] [Related]
63. Simultaneous Quantification of Ivacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis Patients' Plasma by a Novel LC-MS/MS Method.
Pigliasco F; Cafaro A; Stella M; Baiardi G; Barco S; Pedemonte N; D'Orsi C; Cresta F; Casciaro R; Castellani C; Calevo MG; Mattioli F; Cangemi G
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831163
[TBL] [Abstract][Full Text] [Related]
64. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
[TBL] [Abstract][Full Text] [Related]
65. Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis.
Olivier M; Kavvalou A; Welsner M; Hirtz R; Straßburg S; Sutharsan S; Stehling F; Steindor M
Front Pharmacol; 2023; 14():1176815. PubMed ID: 37229253
[No Abstract] [Full Text] [Related]
66. Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy.
Stanke F; Pallenberg ST; Tamm S; Hedtfeld S; Eichhorn EM; Minso R; Hansen G; Welte T; Sauer-Heilborn A; Ringshausen FC; Junge S; Tümmler B; Dittrich AM
Front Pharmacol; 2023; 14():1114584. PubMed ID: 36778025
[No Abstract] [Full Text] [Related]
67. Elexacaftor, tezacaftor and ivacaftor: a case of severe rash and approach to desensitisation.
Cheng A; Baker O; Hill U
BMJ Case Rep; 2022 Mar; 15(3):. PubMed ID: 35236685
[TBL] [Abstract][Full Text] [Related]
68. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy.
Lommatzsch ST; Taylor-Cousar JL
Ther Adv Respir Dis; 2019; 13():1753466619844424. PubMed ID: 31027466
[TBL] [Abstract][Full Text] [Related]
69. Dose adjustments of Elexacaftor/Tezacaftor/Ivacaftor in response to mental health side effects in adults with cystic fibrosis.
Spoletini G; Gillgrass L; Pollard K; Shaw N; Williams E; Etherington C; Clifton IJ; Peckham DG
J Cyst Fibros; 2022 Nov; 21(6):1061-1065. PubMed ID: 35585012
[TBL] [Abstract][Full Text] [Related]
70. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
[TBL] [Abstract][Full Text] [Related]
71. Quantitation of cystic fibrosis triple combination therapy, elexacaftor/tezacaftor/ivacaftor, in human plasma and cellular lysate.
Ryan KJ; Guimbellot JS; Dowell AE; Reed-Walker KD; Kerstner-Wood CD; Anderson JD; Liu Z; Acosta EP
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Dec; 1213():123518. PubMed ID: 36371965
[TBL] [Abstract][Full Text] [Related]
72. A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation.
Davies JC; Sermet-Gaudelus I; Naehrlich L; Harris RS; Campbell D; Ahluwalia N; Short C; Haseltine E; Panorchan P; Saunders C; Owen CA; Wainwright CE;
J Cyst Fibros; 2021 Jan; 20(1):68-77. PubMed ID: 32967799
[TBL] [Abstract][Full Text] [Related]
73. Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19.
Hong E; Almond LM; Chung PS; Rao AP; Beringer PM
Clin Pharmacol Ther; 2022 Jun; 111(6):1324-1333. PubMed ID: 35292968
[TBL] [Abstract][Full Text] [Related]
74. Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy.
Heo S; Young DC; Safirstein J; Bourque B; Antell MH; Diloreto S; Rotolo SM
J Cyst Fibros; 2022 Mar; 21(2):339-343. PubMed ID: 34742667
[TBL] [Abstract][Full Text] [Related]
75. Real-world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis.
Keens T; Hoffman V; Topuria I; Elder K; Cerf S; Mulder K; Roberts J; Lysinger J; Del Carmen Reyes M; Berdella M; Cairns AM; Jain M; Ganapathy V; Lou Y; Morcos B; Wu C; Sass L;
Heliyon; 2024 Apr; 10(7):e28508. PubMed ID: 38586424
[TBL] [Abstract][Full Text] [Related]
76. Elexacaftor/tezacaftor/ivacaftor-real-world clinical effectiveness and safety. A single-center Portuguese study.
Lopes K; Custódio C; Lopes C; Bolas R; Azevedo P
J Bras Pneumol; 2023; 49(2):e20220312. PubMed ID: 36820745
[TBL] [Abstract][Full Text] [Related]
77. In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis.
Bihler H; Sivachenko A; Millen L; Bhatt P; Patel AT; Chin J; Bailey V; Musisi I; LaPan A; Allaire NE; Conte J; Simon NR; Magaret AS; Raraigh KS; Cutting GR; Skach WR; Bridges RJ; Thomas PJ; Mense M
J Cyst Fibros; 2024 Feb; ():. PubMed ID: 38388235
[TBL] [Abstract][Full Text] [Related]
78. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
[TBL] [Abstract][Full Text] [Related]
79. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
[TBL] [Abstract][Full Text] [Related]
80. Case Report: When cystic fibrosis, elexacaftor/tezacaftor/ivacaftor therapy, and alpha1 antitrypsin deficiency get together.
Kinuani R; Ezri J; Kernen Y; Rochat I; Blanchon S
Front Pediatr; 2024; 12():1378744. PubMed ID: 38655277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
